3Dreizen S,Mccredie KB,Keating MJ,et al.Nutritional deficiencies in patient receiving cancer chenaotherapy.Pestgrad Med,1990,87:163.
4Wigmore SJ,Plester CE,Richardson RA,et al.Changes in nutritionalstatus associated with unresectable pancreatic cancer.Br J Cancer,1997,75(1):106-109.
5Couch M,Lai V,Cannon T,et al.Cancer cachexia syndrome in head andneck cancer patients:part Ⅰ.diagnosis,impact on quality of life and survival,and treatment.Head Neck,2007,29(4):401-411.
6Lacouture M E, Maitland M L, Segaert S, et al.A proposed EGFR inhibitor dermatologic adverse eventspecifie grading scale from the MASCC skin toxicity study group[J].Supportive Care in Cancer, 2010, 18(4): 509-522.
7Dindo D, Breitenstein S, Hahnloser D, et al.Kinetics of D-dimer after general surgery[J].Blood Coagul Fibrinolysis, 2009, 20(5): 347-352.
8V Essuman, C T Ntim-Amponsah, S Akafo L, et al. Presaatation of retinoblastoma at eye clinic iti Ghana[J]. Ghana Medical, 2010,44( 1 ): 10-15.
9Guillermo L, Chantada, Chantada G L, et al. Clinical Presentation of Retinoblastoma in a Middle-income Country[J]. Pediatr Hematol Oncol, 2012, 34 ( 3 ) : 97-101.
10MacCarthy A, Birch J M, Draper G J, et al.Retinob!astoma: Treatment and survival in Great Britain 1963 to 2002[J]. Br J Ophthalmol, 2009, 93 ( 1 ) : 38-39.
